I-Mab (IMAB)
NASDAQ: IMAB · IEX Real-Time Price · USD
1.750
-0.020 (-1.13%)
At close: May 17, 2024, 4:00 PM
1.800
+0.050 (2.86%)
After-hours: May 17, 2024, 4:28 PM EDT
I-Mab Revenue
In the year 2023, I-Mab had annual revenue of $3.90M, a decrease of -112.27%.
Revenue (ttm)
$3.90M
Revenue Growth
-112.27%
P/S Ratio
34.57
Revenue / Employee
$10,315
Employees
378
Market Cap
134.79M USD
Revenue Chart
* The company reports in CNY currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.90M | 35.69M | -112.27% |
| Dec 31, 2022 | -31.79M | -45.54M | -331.12% |
| Dec 31, 2021 | 13.75M | -222.13M | -94.17% |
| Dec 31, 2020 | 235.88M | 231.60M | 5,403.91% |
| Dec 31, 2019 | 4.29M | -3.50M | -44.94% |
| Dec 31, 2018 | 7.78M | 6.04M | 345.57% |
| Dec 31, 2017 | 1.75M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TruBridge | 336.45M |
| Quipt Home Medical | 185.39M |
| Karyopharm Therapeutics | 140.46M |
| Seer, Inc. | 15.67M |
| Omega Therapeutics | 4.94M |
IMAB News
- 18 days ago - I-MAB Filed 2023 Annual Report on Form 20-F - PRNewsWire
- 6 weeks ago - I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference - PRNewsWire
- 6 weeks ago - I-Mab Announces Closing of the Divestiture of Business Operations in China - PRNewsWire
- 2 months ago - I-Mab Reports Full Year 2023 Financial Results and Business Update - PRNewsWire
- 3 months ago - Biotech firm I-Mab to divest China operations, shift focus to US - Reuters
- 3 months ago - I-Mab Signs Agreement to Divest its Assets and Business Operations in China - PRNewsWire
- 6 months ago - I-Mab Announces Participation at Jefferies and Piper Conferences in November - PRNewsWire
- 7 months ago - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) - PRNewsWire